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Abstract: Enterohemorrhagic Escherichia coli (EHEC) is the most common cause of hemorrhagic colitis
and hemolytic uremic syndrome in human patients, with brain damage and dysfunction the main
cause of acute death. We evaluated the efficacy of urtoxazumab (TMA-15, Teijin Pharma Limited),
a humanized monoclonal antibody against Shiga toxin (Stx) 2 for the prevention of brain damage,
dysfunction, and death in a piglet EHEC infection model. Forty-five neonatal gnotobiotic piglets were
inoculated orally with 3 × 109 colony-forming units of EHEC O157:H7 strain EDL933 (Stx1+, Stx2+)
when 22–24 h old. At 24 h post-inoculation, piglets were intraperitoneally administered placebo or
TMA-15 (0.3, 1.0 or 3.0 mg/kg body weight). Compared to placebo (n = 10), TMA-15 (n = 35) yielded a
significantly greater probability of survival, length of survival, and weight gain (p <0.05). The efficacy
of TMA-15 against brain lesions and death was 62.9% (p = 0.0004) and 71.4% (p = 0.0004), respectively.
These results suggest that TMA-15 may potentially prevent or reduce vascular necrosis and infarction
of the brain attributable to Stx2 in human patients acutely infected with EHEC. However, we do not
infer that TMA-15 treatment will completely protect human patients infected with EHEC O157:H7
strains that produce both Stx1 and Stx2.
Keywords: Shiga toxin; enterohemorrhagic E. coli; gnotobiotic piglets; monoclonal antibody
1. Introduction
Strains of Shiga toxin (Stx)-producing Escherichia coli (STEC) are important foodborne pathogens,
causing severe illness in humans, including hemorrhagic colitis and hemolytic uremic syndrome
(HUS) [1]. STEC isolates from cases of hemorrhagic colitis and/or HUS, or those strains that contain
the genes for production of Shiga toxin (Stx), and an adhesin known as intimin, are classified as
enterohemorrhagic E. coli (EHEC) [2]. The global annual incidence of STEC-related illnesses was
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recently estimated as 2,801,000 acute illnesses, 3890 cases of HUS, 270 cases of end-stage renal disease,
and 230 deaths [3]. Based on data from 2000–2008, the estimated annual incidence of STEC infection in
the United States was 175,905 cases, resulting in 2409 hospitalizations and 20 deaths [4]. About 40% of
HUS cases stemming from EHEC infections require acute dialysis, and brain involvement is the most
frequent cause of acute death [5,6].
EHEC strains cause disease in human patients through a combination of intestinal and
extra-intestinal effects [7]. EHEC are thought to infect the human intestine by a mechanism that
includes intimate attachment to and effacement of intestinal microvilli [8,9], as was originally
demonstrated in a neonatal gnotobiotic piglet model [10,11]. The attaching-and-effacing (A/E) lesions
seen in the gnotobiotic piglet [12,13] and other models are dependent upon the production of the outer
membrane protein, intimin.
EHEC strains produce either or both of the two main types of Stx, viz., Stx1 and Stx2 [14,15].
These toxins bind to their receptor, viz., globotriaosylceramide (Gb3), on the plasma membranes
of cells in host tissues, with particular targeting and significance involving the renal microvascular
endothelial cells in the human host [7,16]. Stx-mediated injury to endothelial cells results in apoptosis,
inflammatory cytokine release, and upregulation of leukocyte adhesion molecules [6,17]. These effects
lead to a prothrombotic state resulting in hemorrhage and thrombosis in the tissues of vital organs,
especially the kidneys and brain, with development of the HUS and brain infarcts [6]. Central nervous
system (CNS) dysfunction is the main cause of acute death in the human patient, and is thought to
involve a combination of effects that include Stx-induced vascular injury, endothelial dysfunction,
hypertension, and electrolyte disorders [6].
Gnotobiotic piglets have been employed as a model for studying the pathogenesis of EHEC
since 1986, when Francis et al. [10] and Tzipori et al. [11] first demonstrated bacterial attachment
and microvillous effacement and diarrhea in piglets inoculated with O157:H7 EHEC strain EDL931,
originating from a 1982 disease outbreak in Oregon. Tzipori et al. [18] and Francis et al. [19] reported
neurological disease in piglets challenged with EHEC strains and collectively demonstrated the
presence of hemorrhages, arteriolar necrosis, and infarcts in the brain. Gnotobiotic piglets developed
petechial hemorrhages in the cerebellum following inoculation with an isolate of EHEC O157:H7 from
a 20-month-old girl that had cerebellar hemorrhages of a very similar appearance [18].
Gnotobiotic piglets also have been used to study the protective effects of passive immunization
against Stx with antibodies administered prior to bacterial challenge. The first studies published
utilized hyperimmune porcine-origin polyclonal antiserum containing antibodies specific for Stx2
given by the oral [20] or intraperitoneal [21] routes, and in both cases passive immunization
protected against brain vascular lesions caused by E. coli O157:H7 infection. In another study,
hyperimmune porcine-origin polyclonal antiserum containing antibodies specific for Stx2e given
via the intraperitoneal route protected conventional weaned pigs against clinical and pathological
evidence of disease following an oral challenge of a wild-type Stx2e+ E. coli porcine isolate [22].
Currently, no approved treatments are available that directly combat or prevent EHEC infection
or disease resulting from infection. The therapeutics that have been most extensively developed
and tested are monoclonal antibodies (MAb) to Stx1 and Stx2 [23]. Nakao et al. [24] reported the
development of a mouse MAb of the immunoglobulin G1 subclass, having k light chains that could
neutralize the cytotoxic activity of Stx2 and variants derived from patient strains, but not that of
variants from animal-derived strains. The Mab, called VTm1.1, was shown to bind to Stx2 B subunits.
Subsequently, VTm1.1 was humanized by combining the complementarity-determining regions of
VTm1.1 with appropriate human framework and constant regions [25]. In order to further improve
binding affinity, several amino acids were changed, which also reduced its potential for stimulating
anti-immunoglobulins in humans. The resultant humanized antibody, called TMA-15, retained affinity
for Stx2 at a level within two-fold of that of the original murine antibody [25].
Animal experiments have been used to test the efficacy of TMA-15. Kimura et al. [25]
demonstrated that TMA-15 prevented death in mice challenged with Stx2. The efficacy of TMA-15
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was further demonstrated in a mouse infection model using virulent EHEC O91:H1 Stx2d+ strain
B2F1, in which case the MAb was administered after bacterial and toxin challenge [26]. In this model,
a time-course analysis of the serum Stx2 level showed that the toxin was detectable from 24 h after
infection. Protection was demonstrated up to 24 h after infection, but not at 48 h post-challenge.
To determine the effective dose, escalating doses were administered at 24 h after infection. Protection of
all mice required a TMA-15 dosage of 1.0 mg/kg. The observations of these studies in mice suggest that
TMA-15 has potential post-exposure application for the prevention of severe complications associated
with EHEC infection. In the present paper, we address this hypothesis using the neonatal gnotobiotic
piglet model, because it closely resembles the young human patient (i.e., children) with regard to
neurological complications in EHEC O157:H7 infection, the main cause of acute death in patients
with HUS.
2. Results
2.1. Effect of TMA-15 Treatment on Piglet Survival to 192 h after EHEC O157:H7 Inoculation
Raw data for each piglet and treatment group in the study is provided in Table S1. Regardless
of dosage level, a significantly greater proportion of piglets treated with TMA-15 survived for 192 h
post-inoculation compared to the placebo-treated piglets (Table 1). The % efficacy of TMA-15 against
mortality was 71.4% (Relative Risk = 0.286, p <0.05).
Table 1. Proportion of piglets by treatment group that survived for 192 h after inoculation with
enterohemorrhagic E. coli (EHEC) O157:H7 *.
Treatment
Litter
Total (%) **
1 2 3 4 5
Placebo 0/2 0/2 0/2 0/2 1/2 1/10 (10.0) a
TMA-15, 0.3 mg/kg † 0/2 NT ‡ 2/3 4/4 3/3 9/12 (75.0) b
TMA-15, 1.0 mg/kg 0/1 NT 3/4 3/3 3/3 9/11 (81.8) b
TMA-15, 3.0 mg/kg 0/2 2/2 1/3 3/3 2/2 8/12 (66.7) b
Pooled TMA-15 data 0/5 2/2 6/10 10/10 8/8 25/35 (71.4) b
* Number survived/number inoculated. ** Total proportion for all 5 litters combined and expressed as a percentage.
† Dosage of TMA-15 in mg/kg body weight, administered intraperitoneally 24 h post-inoculation. ‡ NT, not tested
since the litter contained only 4 piglets, and the a priori study design was to include a minimum of 2 piglets per
treatment group per litter. a,b Unlike superscripts denote significantly different proportions (p < 0.05) based on
Chi-squared and Fisher’s exact test analyses (FREQ Procedure, SAS) which gave similar results.
Overall, piglets treated with TMA-15 survived longer than those treated with the placebo, based
on survival analyses (Figure 1). The probabilities of survival over time for the pooled TMA-15 (n = 35)
and placebo (n = 10) groups were significantly different (Chi-square = 8.3496; p = 0.0039). The median
survival time for the placebo group was 79 h, in contrast to ≥192 h for each of the TMA-15 dosage
and pooled dosage groups. The exact mean survival time for each of the TMA-15 groups could not be
determined since the sets included censored data.
Although a significant effect of TMA-15 treatment compared to placebo was detected as noted
above, a dosage effect was not detected by survival analysis (Chi-square = 0.4429; p = 0.8014; Figure 2).
2.2. Effect of TMA-15 Treatment on Weight Change after EHEC O157:H7 Inoculation
The percent weight change in piglets administered TMA-15 was significantly greater than that of
piglets administered the placebo after EHEC O157:H7 inoculation; however, a TMA-15 dosage effect
was not evident (Table 2). Since weight change was also a function of survival time, the data were
normalized as percent weight change per h and analyzed. Similarly, using this parameter, a significant
treatment effect for TMA-15 (p <0.05), but not a dosage effect was detected.
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Figure 1. Probability of survival over time in piglets treated with TMA‐15 (dashed red line; n = 35) or 
placebo  (solid  blue  line;  n  =  10)  24  h  post‐challenge  inoculation with  enterohemorrhagic  E.  coli 
(EHEC)  O157:H7.  Survival  analysis was  conducted  using  the  Kaplan‐Meier method  (LIFETEST 
procedure  in  SAS).  +  Censored  indicates  that  censored  data  (piglets  surviving  to  the maximal 
observation time of 192 h) were used in the analysis.   
Figure  2.  Probability  of  survival  over  time  in  piglets  treated with  TMA‐15  at  different  dosages   
[0.3 mg/kg (solid blue line; n = 12), 1.0 mg/kg (dashed red line; n = 11), and 3.0 mg/kg (dashed green 
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O157:H7. Survival analysis was conducted using the Kaplan-Meier method (LIFETEST procedure in
SAS). + Censored indicates that censored data (piglets surviving to the maximal observation time of
192 h) were used in the analysis.
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Table 2. Mean weight change and weight change per h in piglets after inoculation with EHEC O157:H7.
Treatment % Weight Change * % Weight Change/h *
Difference in % Weight Change
and % Weight Change/h (in
Parentheses) from External
Non-Toxin Control †
Placebo (n = 10) 5.8 ± 3.5 a 0.04 ± 0.02 a −22.3 ± 1.4 (−0.11 ± 0.1)
TMA-15, 0.3 mg/kg (n =12) 24.8 ± 4.9 b 0.13 ± 0.03 b −3.3 ± 1.5 (−0.02 ± 0.1)
TMA-15, 1.0 mg/kg (n = 11) 30.4 ± 5.0 b 0.15 ± 0.03 b 2.3 ± 1.6 (0.00 ± 0.1)
TMA-15, 3.0 mg/kg (n = 12) 25.7 ± 6.5 b 0.13 ± 0.04 b −2.4 ± 1.7 (−0.02 ± 0.1)
Pooled TMA-15 data (n = 35) 26.9 ± 3.1 b 0.14 ± 0.02 b 1.2 ± 1.2 (−0.01 ± 0.72)
External non-toxin control (n = 2) † 28.1 ± 1.31 b 0.15 ± 0.01 b NA
* Mean ± standard error of mean. % weight change represents the difference in body weight occurring between the
times of administration of treatment (TMA-15 or placebo) and euthanasia or necropsy, if death had already occurred,
expressed as a percentage. % weight change per h represents weight change as previously defined divided by the
number of h represented by the time differential, expressed as a percentage. Means for placebo and pooled TMA-15
groups were compared using Student’s t test (SAS TTEST). Additionally, means for placebo and the 3 dosage
levels of TMA-15 were compared using the GLM (General Linear Model) procedure, LS (Least Squares) Means in
SAS. † Since this study did not include non-inoculated piglets, historical data from age-matched gnotobiotic piglet
controls from another study [27] was used to estimate the extent to which TMA-15 treatment normalized the weight
change. These controls (n = 2) were weighed at the same ages as in the present study (at 1 and 9 days of age, 192 h
apart) prior to inoculation and were raised under comparable conditions (type of milk replacer, frequency, amount,
isolator units, etc.). The % weight change and % weight change per h for the external controls was 28.1 ± 1.31 and
0.15 ± 0.01, respectively. The differences between the means were determined by simple subtraction, whereas that
for SEMs was calculated by the following formula: SEM difference = SQRT ([SD group 1/n1] + [SD group 2/n2]),
where SQRT = square root, SD = standard deviation, and n = number of piglets in group. a,b Unlike superscripts
denote significantly different means (p < 0.05). NA = not applicable.
2.3. Relationship between Presence of Brain Lesions and Signs of CNS Dysfunction or Death
Brain lesions consistent with those reported previously in piglets inoculated with EHEC
O157:H7 [11,18,20,28] were seen histologically as expected, mainly in piglets with signs of CNS
dysfunction. The range of lesions reflected a progression of severity (i.e., from least to most severe):
apoptosis of endothelial cells in blood vessels of all types; hemorrhages; thrombosis of blood vessels of
all types; vacuolation of neuropil; necrosis of neurons (individual, laminar or confluent); and confluent
infarction involving all brain tissue (neurons and neuropil) in one or more layers, e.g., molecular,
granular, Purkinje and white matter layers in cerebellum (Figures S1–S8).
The observed frequencies of piglets having lesions as described above in one or more of the
five brain section areas and neurological signs (signs of CNS dysfunction) are shown in Table 3.
The proportion of piglets with neurological signs concurrent with detectable brain lesions (19/20
(95%)) was significantly greater than the proportion with neurological signs lacking detectable brain
lesions [1/20 (5%)] (p <0.0001). Hence, the manifestation of neurological signs was strongly associated
with, and a predictor of, the presence of brain lesions.
Table 3. Contingency table (2 × 2) comparing numbers of piglets with brain lesions and
neurological signs.
Outcome Brain Lesions Total
Neurological Signs
Absence (0) or Presence (1) 0 1
0 21 4 25
1 1 19 * 20
Total 22 23 45
* The proportion of piglets manifesting neurological signs that had detectable brain lesions [19/20 (95%)] was
significantly greater than the proportion manifesting neurological signs that lacked detectable brain lesions
(1/20 (5%)) (p <0.0001), as determined by Fisher’s exact test (FREQ Procedure, SAS).
All piglets that died (18/18 (100%)) and 5 of 27 (18.5%) that survived had detectable brain lesions
(Table 4).
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Table 4. Contingency table (2 × 2) comparing numbers of piglets with brain lesions and death.
Outcome Brain Lesions Total
Death
Absence (0) or Presence (1) 0 1
0 22 5 27
1 0 18 * 18
Total 22 23 45
* The proportion of piglets that died that had detectable brain lesions (18/18 (100%)) was significantly greater than
the proportion that died that lacked detectable brain lesions (0/18 (0%)) (p <0.0001), as determined by Fisher’s exact
test (FREQ Procedure, SAS).
2.4. Relationship between Extent and Severity of Brain Lesions and Death
Although death was strongly associated with the presence of brain lesions, since some piglets
with brain lesions survived, this suggested that the outcomes of survival or death were directly
related to the extent and severity of these lesions. In order to quantify the extent and severity of brain
lesions and determine whether there was a quantitative relationship between these two parameters
and death in the study, a modified version of the brain ischemia (stroke model) scoring scheme of
Björkman et al. [29] was developed and used. This scheme incorporated all lesions related to ischemia
and both their extent and severity into one score, allowed for comparison of the extent of involvement
of different areas of the brain, and had been previously validated on a piglet brain ischemia model.
The scheme was modified by introducing scores for presence of vascular lesions in the absence of
neuronal or other brain parenchymal necrosis. Using the modified Björkman scheme, the mean brain
lesion score was numerically higher in all five areas of the brain, and the total brain lesion score was
significantly higher (p <0.0001) in piglets that died compared to those that survived (Figure 3). Hence, a
quantitative relationship between brain lesion scores and death was demonstrated using the modified
Björkman scheme.
2.5. Efficacy of TMA-15 for Prevention and/or Reduction of Extent and Severity of Brain Lesions after EHEC
O157:H7 Inoculation
Since a relationship had been established between the extent and severity of brain lesions (as
evidenced by modified Björkman scores) and death, the efficacy of TMA-15 on reduction of these
lesions was determined. The mean total brain lesion score in piglets treated with TMA-15 (pooled
treatment group data) was significantly lower than that of the placebo group (p = 0.0255); hence, a
significant TMA-15 treatment effect was detected (Table 5). The % efficacy of TMA-15 against brain
lesion development was 62.9% (Relative Risk = 0.371; p = 0.0004). The mean scores for each of the
TMA-15 dosage groups also were significantly lower than that of the placebo group (p <0.05), but the
scores for the different dosage level groups were not significantly different from each other. Hence, a
TMA-15 dosage effect was not detected.
2.6. Lack of Effect of TMA-15 Treatment on Diarrhea and Lesions in Organs Other Than the Brain
All piglets in the study developed diarrhea within 24 h post-inoculation with EHEC O157:H7,
regardless of treatment. Similarly, all piglets, regardless of treatment, had coliform bacterial
colonization of the large intestines in association with classical attaching-effacing (A/E) lesions,
and mild to moderate acute multifocal purulent colitis as has been previously reported with EHEC
O157:H7 infection. Hence, TMA-15 treatment had no detectable effect on the clinical or pathological
parameters of enteric disease caused by EHEC infection, i.e., diarrhea, A/E lesions, and purulent
inflammation of the colon.
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compared using Student’s  t  test  (SAS TTEST). Additionally, means  for placebo and  the 3 dosage 
levels  of  TMA‐15 were  compared  using  the GLM  (General  Linear Model)  procedure,  LS  (Least 
Squares) Means in SAS. a,b Unlike superscripts denote significantly different means (p < 0.05). 
Figure 3. Comparison of brain lesion scores in piglets that were moribund and euthanatized or died
(all counted as deaths) during the 192-h post-inoculation period (red ars; n = 18) with scores f those
that survived for 192 h post-inoculation (blue bars; n = 27). Bars show means and standard errors
of brain lesion scores (Y axis) as determined by a modification of the brain ischemia scoring scheme
of Björkman et al. [29]. Coronal section areas of brain examined (X axis) were the same as those as
described by Francis et al. [19] with reference points in parentheses: 1 = medulla oblongata (olivary
nucleus); 2 = cerebellum (cerebellar peduncles); 3 = midbrain (corpora quadrigemina); 4 = cerebrum
and thalamus (interthalamic adhesion); 5 = cerebrum (genu of corpus callosum); total = sum of scores
of all five areas. The mean total lesion score for piglets that survived (2.7 ± 1.6) was significantly
lower (p <0.001) than the mean score for those that died (29.2 ± 2.7), as determined by Student’s t test
(TTEST, SAS).
Table 5. Mean total brain lesion scores in piglets after inoculation with EHEC O157:H7.
Treatment Total Brain Lesion Score *
Placebo (n = 10) 27.5 ± 3.6a
TMA-15, 0.3 mg/kg (n =12) 11.8 ± 5.2b
TMA-15, 1.0 mg/kg (n = 11) 4.7 ± 2.8b
TMA-15, 3.0 mg/kg (n = 12) 10.8 ± 4.8b
Pooled TMA-15 groups (n = 35) 9.3 ± 2.6b
* Mean ± standard error of mean. % weight change represents the difference in body weight occurring between the
times of administration of treatment (TMA-15 or placebo) and euthanasia or necropsy, if death had alread occurred,
expressed as a percentage. % weight change per h represents weight change as previously defined divided by the
number of h represented by the time differential, expressed as a percentage. Means for placebo and pooled TMA-15
groups were compared using Student’s t test (SAS TTEST). Additionally, means for placebo and the 3 dosage levels
of TMA-15 ere comp red using the GLM (G neral Linear Model) procedure, LS (Least Squares) Means in SAS.
a,b Unlike superscripts denote significantly different means (p < 0.05).
Lesions other than those seen in the brain and intestines were limited to the liver, lung, and
kidney, nd seen in a minority of the iglets. Hence, no les ons were seen in the spleens of any of the
piglets in the study. Liver lesions were seen in only three piglets, all of which were in Litter 3, and
consisted of rare thrombi in the microvasculature. Lung lesions were seen in only three piglets, one
each from Litters 1, 3 and 4. Two piglets, one each from Litters 1 and 3, had rare pulmonary thrombi.
One piglet from Litter 4 had mild focal acute purulent bronchopneumonia, which may have occurred
from aspiration of milk replacer containing bacteria. These sporadic lesions seen were either a part of
the natural EHEC infection course (e.g., thrombi in organs) or were circumstantial (e.g., pneumonia in
one piglet) and did not affect the outcome of the study.
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All piglets in the study, regardless of treatment, had one or more lesions in the kidneys consistent
with those previously described with EHEC infection [30,31], but reportedly have not been severe
enough to cause statistically significant renal dysfunction [30]. These lesions consisted of rare
multifocal glomerular thrombosis, rare multifocal thrombotic or proliferative microangiopathy of
afferent arterioles, and rare multifocal apoptosis of tubular epithelial cells (Figures S9–S12). Due to the
lack of evidence of causation of clinical effects in previous studies, no attempt was made to conduct
clinical pathologic assessments of renal function as a part of the study. Further, since these lesions
were present in all piglets of this study and in low numbers, we did not attempt to quantify them.
However, we infer that a reduction in the number of renal lesions per piglet would be needed to assess
a potential effect of TMA-15 treatment.
2.7. Microbiological Tests
Culture of colonic specimens taken from each piglet in the study at necropsy yielded bacteria
whose culture and colony characteristics were consistent with that of the inoculum. No contaminants
were detected in the colonic contents of piglets in Litters 1–4; however, cultures of all piglets in Litter 5
yielded anaerobes whose colony characteristics were consistent with that of Clostridium perfringens.
This organism was presumed to have originated from the skin of the sow and entered the isolator units
at the time of the cesarean surgery for derivation of Litter 5.
2.8. Evaluation of the Potential Effects of Contamination as a Confounder in Litter 5
As with Litters 1–4, no lesions other than those attributable to EHEC O157:H7 infection were
detected in the Litter 5 piglets. However, in order to further address the potential for this contaminant
to serve as a confounder, all statistical analyses were repeated with only the data from Litters 1–4
(n = 35) and the results compared with that of Litters 1–5 (n = 45). A reduction in statistical power
due to the reduction in the number of observations resulted in an increase in the p value for most
comparisons. The only result that significantly changed was the effect of TMA-15 treatment on total
brain lesion score (Table 6). This was the case because in Litter 5, a clear-cut TMA-15 effect had
occurred: both placebo piglets (n = 2) had brain lesion scores that fell within the range of the placebo
piglets in the other litters, and no brain lesions were detected in any of the TMA-15 piglets (n = 8).
We concluded that the anaerobic contaminant did not serve as a confounder in the experiment for
the following reasons: no lesions were seen other than those attributable to EHEC O157:H7 infection;
the placebo piglets were not protected from brain lesions; and, the clinical outcomes and their rate of
occurrence did not differ from that of Litters 1–4.
Table 6. Comparison of P values with and without inclusion of Litter 5 data *.
Response Variable Comparison Test Litters 1–5 (n = 45) Litters 1–4 (n = 35)
Survival Across P and 3 dosages of T Chi-Square 0.0327 0.1362
Survival P versus pooled T Chi-Square 0.0039 0.0210
Survival curve (survival over time) P versus pooled T Kaplan-Meier 0.0165 0.0658
Weight change P versus pooled T t test 0.0014 0.0038
Weight change/h P versus pooled T t test 0.0073 0.0132
Brain lesions and neurological signs Relationship Fisher’s exact test <0.0001 <0.0001
Brain lesions and death Relationship Fisher’s exact test <0.0001 <0.0001
Total brain lesion score S versus D t test <0.0001 <0.0001
Total brain lesion score P versus T t test 0.0010 0.0440
% Efficacy against death † P versus T 1-Relative Risk <0.0004 <0.001
% Efficacy against brain lesions ‡ P versus T 1-Relative Risk <0.0004 <0.0086
* p = placebo-treated; T = TMA-15-treated; pooled T = data from 3 dosage groups pooled; S = survived; D = died
(includes moribund piglets that were euthanatized); t test = Student’s t test. † The % efficacy of TMA-15 against
death for n = 45 was 71.4%, compared to 66.7% for n = 35. ‡ The % efficacy of TMA-15 against brain lesions for
n = 45 was 62.9%, compared to 51.9% for n = 35.
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3. Discussion
The results of this study demonstrate that the humanized anti-Stx2 monoclonal antibody TMA-15
is highly protective against neuropathological sequelae of EHEC infection in the neonatal gnotobiotic
piglet model when administered within 24 h after the onset of infection. This study extends the
observations made by Yamagami et al. [26] who reported that TMA-15 increased the survival of
mice when administered 24 h after challenge with 1010 CFU EHEC. These results also extend those
of Mukherjee et al. [32] and Sheoran et al. [33] who reported that an anti-Stx2 MAb increased the
survival of gnotobiotic piglets after EHEC inoculation. The studies by Mukherjee et al. [32] and
Sheoran et al. [33] differed from the present one in several ways: type of MAb and specific one used;
MAb dosage levels; EHEC O157:H7 challenge strain used; EHEC inoculum level; length of observation
period after challenge; range of response variables monitored; response variables subjected to statistical
hypothesis testing (Table 7). The present study addressed three MAb dosage levels and one time of
administration, but provided a more extensive analysis of its efficacy against brain lesions, with the
development and implementation of a relevant brain lesion scoring scheme, and statistical hypothesis
testing of all main response variables.
Table 7. Comparison of studies evaluating the efficacy of anti-Stx2 monoclonal therapy to prevent
systemic complications following intestinal infection with EHEC O157:H7 in gnotobiotic piglets.
Parameter Present Study Reference [32] Reference [33]
Monoclonal antibody type Humanized Human Human
Monoclonal antibody (isotype) TMA-15 (IgG1κ) 3E9, 5H8, 2F10, 5C12 (IgG1κ) 5C12 (IgG1κ)
Monoclonal antibody Stx subunit
specificity B A, B, A, A * A
Monoclonal antibody dosage
(h post-inoculation)
0.3, 1.0 or 3.0 mg/kg (24) 3.0 mg (6 or 12) 1.5 or 3.0 mg/kg (24)
0.05, 0.1, 0.2, 0.4, 0.75, 3.0 or 6.0
mg/kg (48)
EHEC inoculum strain (Stx type) EDL933 (Stx1+, Stx2+) 86-24 (Stx2+) 86–24 (Stx2+)
EHEC inoculum level ~3 × 109 CFU † ~1 × 101◦ CFU ~1 × 1010 CFU
Age of pig in hours at time of
EHEC inoculation 24 24 24
Maximum number of days of
observation after inoculation 8 10 14
Fluid therapy used to control
dehydration after inoculation No No Yes
Response variables monitored
Diarrhea, anorexia, lethargy,
anorexia, dehydration, weight
change, weight change per h,
CNS signs, moribund state,
survival, brain lesions (5 levels),
brain lesion score (5 levels)
Diarrhea, dehydration, CNS
signs, brain lesions (2 levels:
cerebral cortex and
cerebellum), survival, serum
human IgG concentration
Diarrhea, anorexia, depression,
dehydration, weight loss,
brain lesions (2 levels: cerebral
cortex and cerebellum),
survival, serum human
IgG1(κ) concentration
Response variables statistically
analyzed by hypothesis testing
Weight change, weight change
per h, CNS signs, survival, brain
lesions (5 levels), brain lesion
score (5 levels)
Survival Not indicated
* Order of listing of Shiga toxin subunit specificities refers to respective order of monoclonal antibodies listed in row
above. † CFU, colony-forming units.
In the present study, infarcts and vascular lesions, including arteriolar necrosis were seen in all five
coronal section areas of brain examined, and TMA-15 was demonstrably effective for the prevention or
reduction of these lesions. In addition, the study addressed whether Stx2-associated kidney lesions as
had been previously reported [30,31] were present. Renal lesions as previously reported were seen in
all piglets, but the effect of TMA-15 on their extent was difficult to evaluate since these lesions were
low in number, yet were seen in all piglets, regardless of their clinical outcome or brain involvement.
Although piglets infected with EHEC O157:H7, including those with neurological signs and brain
lesions have thrombotic microangiopathy and other lesions shown to be due to Stx2 [30,31], these
piglets do not have significantly different serum chemistry values that constitute evidence of renal
uremia [30]. Consistent with this conclusion, earlier studies involving gnotobiotic piglets inoculated
with EHEC O157:H7, including those that developed neurological signs and brain lesions as seen in
the present study, had no evidence of renal compromise based on serum chemistries [34].
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The pig is an excellent model for human brain anatomy and pathophysiology, and in this regard
has frequently been used to study the effects of hypoxia and ischemia [35]. The advantages of the
gnotobiotic piglet as a model to study Stx-induced systemic lesions and disease effects in EHEC
infection, in particular those affecting the brain, have further been noted [36–38]. It is especially
important to note that a significant proportion of children [18,39–42], as opposed to adults [43] dying
from HUS, most of which are due or thought to be due to EHEC infection, develop hemorrhages,
microangiopathy, and infarcts in the brain. The vascular and ischemic lesions (microangiopathy and
infarcts) in these patients closely resemble those seen in the gnotobiotic piglet model, as in the present
study and previously reported. Hence, a determination of the efficacy of an intervention such as
TMA-15 for the prevention or reduction of these lesions, and usage of an appropriate pathology scoring
scheme is highly warranted. Weaknesses of the neonatal gnotobiotic piglet EHEC O157:H7 infection
model are that the piglets do not develop: (1) hemolytic anemia; (2) thrombocytopenia; (3) acute kidney
injury or consistent lesions that result in azotemia or uremia; (4) a high incidence of bloody diarrhea or
hemorrhagic colitis [28,30].
EDL933 was used as the challenge strain because it has a high level of virulence in gnotobiotic
pigs, and with a high degree of regularity causes CNS disease and brain lesions in these animals [19,28].
In previous neonatal gnotobiotic piglet studies it reliably induced brain lesions and, although it
produces both Stx1 and Stx2, CNS signs and brain lesions were associated with Stx2 but not Stx1 [19].
A derivative of EDL933 that lost the Stx2-converting phage but retained the Stx1-converting phage
(strain 933D) did not cause CNS signs or brain lesions in the neonatal gnotobiotic piglet EHEC
O157:H7 enteric infection model [19]. In a subsequent large-scale study, using 100 gnotobiotic piglets
and 20 EHEC O157:H7 strains, the same conclusions were drawn. The amount of Stx2 produced by the
strain was correlated with a reduction in survival, manifestation of CNS signs, and brain infarcts [28].
In that same study, the amount of Stx1 produced by the strain was not correlated with length of
survival, CNS signs or brain infarcts. In a study by another group, gnotobiotic piglets were inoculated
with isogenic Stx1+ and Stx2+ deletion mutants of EDL933 [44]. CNS signs were only seen with the
wild-type parent (Stx1+, Stx2+) and Stx2+-only mutant derivatives. One of six piglets inoculated
with an Stx1+ -only mutant derivative had two discrete focal lesions in the brain, but no CNS signs.
Hence, Stx1 production by EDL933 in enteric infection of neonatal gnotobiotic piglets has very rarely
been associated with CNS lesions and, to our knowledge, yet been shown to cause CNS signs. For
these reasons, we did not consider production of Stx1 by EDL933 to be a confounder in the present
study. However, it should be noted that Stx1 administered parenterally in relatively large doses to the
neonatal gnotobiotic piglet can result in development of the same brain lesions as those attributed to
Stx2 in the enteric bacterial infection model [45]. Hence, the Stx serum concentration that occurs in the
infection would appear to be a key.
In conclusion, this study demonstrated that urtoxazumab (TMA-15), a humanized monoclonal
antibody specific for Stx2 and previously shown to be safe in human patients, provides significant
protection against brain lesions, neurological signs, and death resulting from brain involvement when
administered within 24 h after the onset of EHEC infection in the neonatal gnotobiotic piglet model.
These results suggest that TMA-15 may potentially prevent or reduce vascular necrosis and infarction
of the brain attributable to Stx2 in human patients acutely infected with EHEC. Since CNS disease in the
gnotobiotic piglet following enteric infection with EHEC O157:H7 is predominantly, if not exclusively,
the result of toxic effects of Stx2 and TMA-15 is specific for Stx2, we infer that protection in the present
study was the result of Stx2 neutralization. We do not infer that TMA-15 treatment will result in
complete protection against systemic effects in human patients resulting from enteric infections with
EHEC O157:H7 strains that produce both Stx1 and Stx2. Further studies with TMA-15 to define the
effects of dosage and time of treatment in relation to onset of EHEC infection are warranted.
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4. Materials and Methods
4.1. Monoclonal Anti-Stx2 Antibody and Placebo Control
TMA-15, a humanized mouse MAb against Stx2, was prepared as described elsewhere [25], and
provided by Teijin LLC in sealed ampules (Lot Numbers TEIn004 and TEIs004) which were received
on 12 October 2008. The ampules, each containing 5 mL TMA-15 at a concentration of 4 mg/mL,
were stored at 4 ◦C and opened immediately before use. Prior studies conducted at Teijin LLC had
determined that TMA-15 was stable for ≥2 years. At the time of use, TMA-15 was diluted to the
desired concentration (0.3, 1.0 or 3.0 mg/kg body weight) with physiological saline. Placebo (MAb
diluent) was also provided by Teijin LLC in sealed ampules, stored under the same conditions as
TMA-15, and used without dilution. The placebo and TMA-15 diluent were an aqueous solution
(pH 6.0) consisting of 20 mM sodium citrate, 60 mM sodium chloride, 4% w/v sucrose, and 0.01% w/v
Polysorbate 80. Both TMA-15 and placebo were obtained from ampules using a filter needle.
4.2. Ethical Statement and Animal Care
The care and use of animals for these experiments was approved by the South Dakota State
University Institutional Animal Care and Use Committee under assurance number #A3958-01 and
approval number 06-A014 (23 March 2006 with modification on 25 September 2008). Animal
experiments began on 16 January 2009 and ended on 8 August 2009. Late term pregnant sows
were purchased from local commercial producers and subjected to cesarean section for the delivery of
gnotobiotic piglets on the 112th day of gestation (with full term being 114 days in pigs). Serological
tests were performed to confirm that the sows had not been exposed to porcine reproductive and
respiratory syndrome virus [46] or porcine parvovirus [47], either of which could cause transplacental
infection and complicating disease effects. Cesarean section surgeries were conducted under aseptic
conditions by methods previously described [48]. Piglets were reared in stainless steel isolators fitted
with flexible plastic canopies with two sets of sleeve-attached gloves for animal and supply handling.
Each isolator housed up to 4 piglets, with each animal in an individual pen. Isolator rooms were
maintained in an ambient temperature of 33 ◦C, which is optimal for rearing neonatal piglets. Piglets
were fed a sterile, commercial milk replacer (EsbiLac, PetAg, Ihync, Hamilton, IL, USA) three times
daily, gradually increased in amount to accommodate for the growth requirements of the animals.
4.3. Administration of TMA-15 and Placebo Control
TMA-15 and placebo were administered by bolus injection into the peritoneal cavity using a
disposable syringe and needle at a dose volume of 2.5 mL/kg BW, and were given only once per piglet
at 24 h after EHEC O157:H7 strain EDL933 inoculation. A preliminary study confirming that TMA-15
is absorbed into the bloodstream of neonatal gnotobiotic piglets following intraperitoneal injection
and establishes high anti-Stx 2 titers, including 24 h post-inoculation with EHEC O157:H7 24 h, was
conducted with other litters of gnotobiotic piglets prior to the present study. In that study, 19 piglets
originating from 2 litters were divided at random and administered TMA-15 at a dosage of 3.0 mg/kg
BW (n = 15) or placebo (n = 4) (Table S2). Anti-Stx2 titers were determined at varying time intervals
up to 192 h (Table S2). Anti-Stx2 titers were determined with a validated ELISA with a lower limit
of quantification of 100 ng/mL (MDS Pharma Service, Inc., St. Laurent, QB, Canada). High serum
anti-Stx2 titers were maintained through a 168 h post-TMA-15 administration period, which in turn
had been given 24 h post-inoculation with EHEC O157:H7 (Table S3, Figures S13 and S14). In this
study, 10 of 15 piglets treated with TMA-15 at a dosage of 3.0 mg/kg survived (66.7%), compared to
0 of 4 placebo piglets.
4.4. Bacterial Strain and Inoculum
Escherichia coli strain EDL933 (O157:H7; Stx1, Stx2; ATCC®43895) originally obtained from Centers
for Disease Control and Prevention (CDC), Atlanta, Georgia, and stored in liquid nitrogen, was used
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in this study. EDL933 was used as the challenge strain because it has a high level of virulence in
gnotobiotic pigs, and with a high degree of regularity causes CNS disease and brain lesions in these
animals [19,28]. The bacterium was inoculated in BBL trypticase soy broth (TSB, Becton, Dickinson,
Sparks, MD, USA) and incubated for 12–18 h at 37 ◦C. Piglets received 3 mL of the inoculated medium
which contained approximately 3 × 109 colony forming units (CFU), and was delivered per os 22–24 h
after birth along with a milk replacer meal.
An additional preliminary study (separate from the study described in Section 4.3) to determine
the peripheral blood concentrations of Stx2 over time after oral inoculation of EHEC O157:H7 strain
EDL933 at an inoculum level of 3 × 109 CFU in 22–24 h-old gnotobiotic piglets was conducted with
other litters under the same conditions and methodologies prior to the present study. Twenty-nine
gnotobiotic piglets originating from 3 litters were inoculated as described above with EDL933 and
jugular vein blood samples were obtained, with none of these piglets having been treated with placebo
or TMA-15 (Table S4). Only 2 of 29 piglets survived the 192-h observation period (Table 2) and 1 of
these had CNS signs at 192 h post-inoculation. All 27 piglets that died before 192-h post-inoculation,
displayed CNS signs.
Blood samples from these piglets were centrifuged immediately after removal from the isolator
units, frozen at −76 ◦C, and then shipped on dry ice to SRL Medisearch, Inc. (Tokyo, Japan), Sample
Measurement Section, Hachioji 3rd Laboratory, 153 Komiya-cho, Hachioji, Tokyo 192-0031, Japan.
At this laboratory, the Stx2 serum concentrations were determined by an ELISA that had been validated
for piglet serum samples with the lower limit of quantification (LLOQ) determined to be 10 pg/mL.
Individual serum concentration curves are shown in Figure S15. Stx2 was detected within 12 h
post-inoculation in 8 of 13 piglets, indicating that Stx2 had entered the blood circulation in a short
period after EDL933 inoculation. Serum Stx2 concentrations increased in a time-dependent manner
from the first to the second scheduled bleeding in all piglets, and until the terminal time point in
16 of 23 piglets. The other 7 piglets slowed a slight decrease or no change from the second bleeding
to bleeding at euthanasia. The relationship between terminal time point and terminal Stx2 serum
concentration in each piglet is shown in Figure S16. Serum Stx2 titers varied substantially from piglet
to piglet, such that no statistically significant trends could be established predicting a lethal endpoint,
although the data did confirm the presence of Stx2 in the blood of inoculated piglets in the absence of
TMA-15 treatment, and a trend for an increase in Stx2 serum concentrations over time for at least the
first 72 h after inoculation (the limit of sampling other than immediately prior to death).
4.5. Piglet Observation and Sample Collection
Subsequent to inoculation, piglets were clinically monitored every 4 h until signs of CNS disease
appeared, after which the affected piglets were monitored every 2 h. Clinical signs monitored included:
diarrhea, weight loss, dehydration (eyes sunken in orbits), lethargy, anorexia, ataxia, head tilt or
circling, nystagmus, inability to stand, lateral recumbency, moribund state (see definition, below),
opisthotonus, and tonic-clonic convulsions (“paddling”). Piglets were weighed at the time of TMA-15
inoculation and again at the time of euthanasia, before necropsy. Infected animals judged by the
examiner to be moribund were immediately subjected to euthanasia. For the purposes of this study,
the moribund state was defined as irreversible lateral recumbency (which also occurred in some cases
concurrent with opisthotonus and convulsions) and/or extended anorexia (missing 2 consecutive
meals). Animals that survived (i.e., did not become moribund) were euthanatized 192 h post-challenge
at the termination of the observation period. Euthanasia was accomplished by intramuscular injection
of Telazol®(Fort Dodge, IA, USA) at a dosage of 6 mg/kg body weight (3.0 mg/kg tiletamine and
3.0 mg/kg zolazepam) to induce unconsciousness and general anesthesia [49] followed by electrocution.
This protocol was in accordance with the AVMA Guidelines on Euthanasia [50], and approved by the
South Dakota State University Institutional Animal Care and Use Committee.
At the time of death, body weights were recorded and piglets were subjected to necropsy and
specimen collection. Specimens were collected for histopathological examination, which included:
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brain, ileum, cecum, colon, rectum, liver, lung, spleen, and kidney. These specimens were fixed in
10% neutral buffered formalin, and subsequently processed, sectioned, placed on glass microscope
slides, and stained with hematoxylin and eosin for histopathological examination by standard
procedures. Prior to tissue processing, formalin-fixed brains were grossly coronally-sectioned to
allow for examination of tissue in the following areas (anatomic reference points): medulla oblongata
(olivary nucleus); cerebellum with medulla oblongata (cerebellar pedunucles); midbrain (corpora
quadrigemina); and two levels of cerebrum (interthalamic adhesion and genu of corpus callosum), as
previously described [19].
In addition to the tissues for histopathology, a fresh, unfixed segment of the colon was collected at
the time of necropsy for bacterial culture to test for presence of the inoculated strain, and to assess for
potential contamination. Colonic contents were obtained aseptically from the specimens and subjected
to direct culture at 37 ◦C on 5% sheep blood agar in trypticase soy agar base (Difco Laboratories, Detroit,
MI, USA) in an aerobic environment for 18 h, or in an anaerobic chamber for 48 h. After incubation,
cultures were examined for organisms whose colony or cultural characteristics were consistent or
inconsistent with the inoculum.
4.6. Experimental Objective and Design
The overall goal of this work was to evaluate the efficacy of urtoxazumab (TMA-15) for prevention
of neurological complications of EHEC O157:H7 infection using the neonatal gnotobiotic piglet model.
A total of 45 piglets originating from 5 litters were used in the study with piglets in each litter selected
at random for assignment to treatment groups. To control for litter variability, each litter was divided
such that 2 piglets at random were assigned to the placebo group, and 2 or more piglets at random
were assigned to each TMA-15 dosage group (Table 8). If the litter contained an odd number of piglets,
the extra piglets were placed at random into 1 or more TMA-15 dosage groups. If the litter contained
only 4 piglets, the 2 assigned at random to TMA-15 were placed into the 3.0 mg/kg group.
Table 8. Number of piglets used in the study.
Litter Placebo
TMA-15 Dosage (mg/kg Body Weight)
Total
0.3 1.0 3.0
1 2 2 1 2 7
2 2 0 0 2 4
3 2 3 4 3 12
4 2 4 3 3 12
5 2 3 3 2 10
Total 10 12 11 12 45
4.7. Histological Evaluation of Tissues for Microscopic Lesions
Sections of tissues that were collected at necropsy and processed by routine methods for
histopathology were examined by one of the authors (R.A.M.) who was blinded to the treatment
group. Brain tissues were scored from 0–12 for the degree of injury using a modified version of the
scheme described by Björkman et al. [29] (Table 9). The scheme was based on four categories of
morphological changes, which were cumulative and of increasing severity. The first category consisted
of necrosis of vascular intimal and/or medial cells with thrombosis and hemorrhage (grade 1–3) and
no evidence of neuronal or other brain parenchymal necrosis. The second was necrosis of individual
neurons (grade 4–6). The third was necrosis of a group or layer of neurons, termed laminar necrosis
(grade 7–9). The fourth was necrosis of all cells within a defined area, and was referred to as a confluent
necrosis (grade 10–12). Variations in scores within these categories reflected the extent of the lesions
within a brain section. Total neuropathology scores were calculated as the sum of the scores from all
five brain section areas.
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Table 9. Neuropathological scoring scheme.
Neuropathological Score Percentage of Area Affected Morphological Changes
0 0 No injury
1 <20
Vascular necrosis with thrombosis and hemorrhage2 20–50
3 >50
4 <20
Neuronal necrosis5 20–50
6 >50
7 <20
Laminar necrosis8 20–50
9 >50
10 <20
Confluent necrosis11 20–50
12 >50
Following routine histopathological examination for any type of abnormality, sections of other
tissues were in particular noted for lesions related to EHEC infection. Sections of intestinal tissues
(jejunum, ileum, cecum, spiral colon, and rectum) were examined and noted for presence of coliform
bacteria, A/E lesions, and inflammatory changes consistent with EHEC infection. Kidney tissue
sections were examined and noted for presence of hemorrhage, thrombosis, microangiopathy, and
tubular epithelial necrosis and apoptosis. Sections of liver, spleen, and lung were examined and noted
in particular for presence of thrombotic and inflammatory lesions.
4.8. Statistical Analysis
Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Statistically significant results were represented by values of p <0.05. For those variables where
there were but two treatments, a t-test (with Satterthwaite’s correction for degrees of freedom when
heteroscedasticity was present) was run with a Wilcoxon Rank Sum non-parametric test to confirm the
results. In all cases, the two tests indicated similar results. For more than two treatments the usual
analysis of variance with the non-parametric equivalent (Kruskal Wallis test) was run. For two-factor
experiments a two-way analysis of variance was run, in which case only the treatment was significant
and never the factor “time” or the interaction. For correlations, both the Pearson and non-parametric
Spearman’s correlation were conducted with similar results. The LIFETEST procedure with adjustment
for censored data was used to compute survival curves (nonparametric estimates of the survivor
function) by the product-limit (Kaplan-Meier) method.
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Figure S1. Low-magnification photomicrograph of cerebrum of placebo control piglet (No. 2F-1D) that was
euthanatized when it became moribund 67 h post-inoculation with EHEC O157:H7 strain EDL933. Three foci
of infarction (outlined by rectangles) are seen, which at this magnification appear as areas of pallor. Bar in
lower right corner = 1 mm. Original objective magnification = 2x. Hematoxylin and eosin stain. Figure S2.
Higher magnification of area within box no. 3 in previous photomicrograph. Area of pallor includes vacuolated
neuropil and shrunken, pyknotic cells. Borders of most severely affected area are denoted by arrows. Area in
lower left corner below the arrows is also affected, perhaps with less severe neuropil vacuolation. Bar in lower
right corner = 200 µm. Original objective magnification = 10x. Hematoxylin and eosin stain. Figure S3. Higher
magnification of area within infarct is shown in previous photomicrograph. Neuron No. 1 is necrotic, as evidenced
by being shrunken with pyknotic nucleus and eosinophilic perikaryon. Neuron No. 2 is also necrotic, as evidenced
by being shrunken with karyolytic nucleus and eosinophilic perikaryon. Other neurons in the figure (unlabeled)
are necrotic. Neuropil is pale-staining and vacuolated. Bar in lower right corner = 20 µm. Original objective
magnification = 60x. Hematoxylin and eosin stain. Figure S4. Photomicrograph of medulla oblongata of placebo
control piglet (no. 2F1B) that was euthanatized when it became moribund 33 h after inoculation with EHEC
O157:H7 strain EDL933. A fibrin thrombus (horizontal arrow with label) with entrapped red blood cells occluding
a venule is seen in the center of the field. Fibrin strands are seen within a perivascular space (vertical arrow
with label). Bar in lower right corner = 20 µm. Original objective magnification = 60x. Hematoxylin and eosin
stain. Figure S5. Photomicrograph of medulla oblongata is shown in previous figure. Endothelial cells within
a venule show the morphologic hallmarks of apoptosis (arrows with label). Bar in lower right corner = 20 µm.
Original objective magnification = 60x. Hematoxylin and eosin stain. Figure S6. Photomicrograph of cerebellum
of piglet (No. 3F1C) treated with TMA-15 (3.0 mg/kg) 24 h post-inoculation with EHEC O157:H7 strain EDL933.
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This piglet was the only one in the treatment group that became moribund (75 h post-inoculation). Lesions
seen in this section include multiple coalescing infarcts (confluent necrosis) involving the molecular, granular,
Purkinje and white matter layers, and associated hemorrhage. Bar in lower right corner = 100 µm. Original
objective magnification = 20x. Hematoxylin and eosin stain. Figure S7. Photomicrograph of mesencephalon
of placebo control piglet (No. 2F1B). A ring-shaped area of hemorrhage caused by circumferential bleeding
around a necrotic arteriole is seen in the white matter in the center of the field. The material in the center of the
lesion (arrow) is fibrin. Bar in lower right corner = 50 µm. Original objective magnification = 40X. Hematoxylin
and eosin stain. Figure S8. Photomicrograph of thalamus from same piglet is shown in previous figure. A
thrombus (arrow) is seen in a venule in the lower left corner. The brain parenchyma immediately surrounding
the thrombosed vessel is infarcted, as evidenced by necrotic neurons and other cells, and vacuolated neuropil.
Bar in lower right corner = 50 µm. Original objective magnification = 40x. Hematoxylin and eosin stain. Figure
S9. Photomicrograph of kidney of piglet 2F1C which was treated with TMA-15 at a dosage of 3 mg/kg BW and
survived to 192 h post-inoculation with EHEC O157:H7 strain EDL933. Glomerulus in center of field contains
capillary thrombi (horizontal arrows), and is hemorrhagic (vertical arrow). This piglet did not develop signs
of CNS dysfunction and had no detectable brain lesions. Bar in lower right corner = 20 µm. Original objective
magnification = 60x. Hematoxylin and eosin stain. Figure S10. Photomicrograph of kidney of piglet 3F2D which
was treated with TMA-15 at a dosage of 0.3 mg/kg BW and survived to 192 h post-inoculation with EHEC
O157:H7 strain EDL933. Two arterioles in the center of the field (vertical arrows) have undergone proliferative
microangiopathy, as evidenced by intimal proliferation that has thickened the walls and obliterated the lumens of
these vessels. In addition, some myocytes in the tunica media have undergone fibrinoid change or coagulative
necrosis. This piglet did not develop signs of CNS dysfunction and had no detectable brain lesions. Bar in
lower right corner = 20 µm. Original objective magnification = 60x. Hematoxylin and eosin stain. Figure S11.
Photomicrograph of kidney of piglet 3F3D which was treated with TMA-15 at a dosage of 1.0 mg/kg BW and
survived to 192 h post-inoculation with EHEC O157:H7 strain EDL933. An arteriole in the center of the field
(vertical arrow) has undergone thrombotic microangiopathy with complete obliteration its lumen. Some myocytes
in the tunica media have undergone fibrinoid change or coagulative necrosis with karyorrhexis and karyolysis
of nuclei. This piglet did not develop signs of CNS dysfunction and had no detectable brain lesions. Bar in
lower right corner = 20 µm. Original objective magnification = 60X. Hematoxylin and eosin stain. Figure S12.
Photomicrograph of kidney of piglet 2F1B which was treated with placebo and died 67 h post-inoculation with
EHEC O157:H7 strain EDL933. A renal tubule epithelial cell in the center of the field has undergone apoptosis,
as evidenced by the presence of bleb fragments (arrows). Bar in lower left corner = 20 µm. Original objective
magnification = 60x. Hematoxylin and eosin stain. Figure S13. Mean serum TMA-15 concentrations (ng/ml) over
time in neonatal gnotobiotic piglets inoculated with EHEC O157:H7 and treated by intraperitoneal injection with
TMA-15 (3.0 mg/kg) 24 h after bacterial inoculation. Figure S14. Serum TMA-15 concentrations (ng/ml) over
time in individual neonatal gnotobiotic piglets inoculated with EHEC O157:H7 and treated by intraperitoneal
injection with TMA-15 (3.0 mg/kg) 24 h after bacterial inoculation. Key to piglet ID is shown in Table S3. Figure
S15. Serum Stx2 concentrations over time in individual neonatal gnotobiotic piglets after oral inoculation with
EHEC O157:H7 strain EDL933 at 22–24 h of age. The key in the upper left hand corner shows the identification
number of individual piglets, all of which were given the same treatment except time of blood sampling. The first
number in the piglet identification designates litter of origin (litter 1 or litter 2). Table 8 shows the study design.
Figure S16. Relationship between terminal time (last serum sample before death) and serum Stx2 concentrations
in neonatal gnotobiotic piglets after oral inoculation with EHEC O157:H7 strain EDL933 at 22–24 h of age (n = 29).
Serum concentrations of two surviving piglets were plotted at 196–h post-inoculation. Table S1. Raw data file
for the study. Table S2. Schedule for blood sampling to measure serum TMA-15 concentrations over time in
neonatal gnotobiotic piglets after inoculation at 22–24 h of age with EHEC O157:H7 strain EDL933. Table S3.
Serum concentrations of TMA-15 in individual piglets after single intraperitoneal administration of 3.0 mg/kg.
Table S4. Schedule for blood sampling to measure Stx2 serum concentrations over time in neonatal gnotobiotic
piglets after inoculation at 22–24 h of age with EHEC O157:H7 strain EDL933.
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References
1. Kaper, J.B.; O’Brien, A.D. Overview and historical perspectives. Microbiol. Spectrum 2014, 2. [CrossRef]
[PubMed]
2. Croxen, M.A.; Law, R.J.; Scholz, R.; Keeney, K.M.; Wlodarska, M.; Finlay, B.B. Recent advances in
understanding enteric pathogenic Escherichia coli. Clin. Microbiol. Rev. 2013, 26, 822–880. [CrossRef]
[PubMed]
3. Majowicz, S.E.; Scallan, E.; Jones-Bitton, A.; Sargeant, J.M.; Stapleton, J.; Angulo, F.J.; Yeung, D.H.; Kirk, M.D.
Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: A systematic review
and knowledge synthesis. Foodborne Pathog. Dis. 2014, 11, 447–455. [CrossRef] [PubMed]
4. Scallan, E.; Hoekstra, R.M.; Angulo, F.J.; Tauxe, R.V.; Widdowson, M.A.; Roy, S.L.; Jones, J.L.; Griffin, P.M.
Foodborne illness acquired in the United States—Major pathogens. Emerg. Infect. Dis. 2011, 17, 7–15.
[CrossRef] [PubMed]
5. López, E.L.; Contrini, M.M.; Glatstein, E.; González Ayala, S.G.; Santoro, R.; Allende, D.; Ezcurra, G.;
Teplitz, E.; Koyama, T.; Matsumoto, Y.; et al. Safety and pharmacokinetics of urtoxazumab, a humanized
monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with
Shiga-like toxin-producing Escherichia coli. Antimicrob. Agents Chemother. 2010, 54, 239–243. [CrossRef]
[PubMed]
6. Trachtman, H.; Austin, C.; Lewinski, M.; Stahl, R.A. Renal and neurological involvement in typical Shiga
toxin-associated HUS. Nat. Rev. Nephrol. 2012, 8, 658–669. [CrossRef] [PubMed]
7. Karpman, D.; Ståhl, A.L. Enterohemorrhagic Escherichia coli pathogenesis and the host response.
Microbiol. Spectrum 2014, 2. [CrossRef] [PubMed]
8. McWilliams, B.D.; Torres, A.G. Enterohemorrhagic Escherichia coli adhesins. Microbiol. Spectr. 2014, 2.
[CrossRef] [PubMed]
9. Stevens, M.P.; Frankel, G.M. The locus of enterocyte effacement and associated virulence factors of
enterohemorrhagic Escherichia coli. Microbiol. Spectr. 2014, 2. [CrossRef] [PubMed]
10. Francis, D.H.; Collins, J.E.; Duimstra, J.R. Infection of gnotobiotic pigs with an Escherichia coli O157:H7 strain
associated with an outbreak of hemorrhagic colitis. Infect. Immun. 1986, 51, 953–956. [PubMed]
11. Tzipori, S.; Wachsmuth, I.K.; Chapman, C.; Birner, R.; Brittingham, J.; Jackson, C.; Hogg, J. The pathogenesis
of hemorrhagic colitis caused by Escherichia coli O157:H7 in gnotobiotic piglets. J. Infect. Dis. 1986, 154,
712–716. [CrossRef] [PubMed]
12. Donnenberg, M.S.; Tzipori, S.; McKee, M.L.; O’Brien, A.D.; Alroy, J.; Kaper, J.B. The role of the eae gene of
enterohemorrhagic Escherichia coli in intimate attachment in vitro and in a porcine model. J. Clin. Investig.
1993, 92, 1418–1424. [CrossRef] [PubMed]
13. McKee, M.; Melton-Celsa, A.R.; Moxley, R.A.; Francis, D.H.; O’Brien, A.D. Enterohemorrhagic Escherichia coli
O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to HEp-2 cells. Infect. Immun.
1995, 63, 3739–3744. [PubMed]
14. Melton-Celsa, A.R. Shiga toxin (Stx) classification, structure, and function. Microbiol. Spectr. 2014, 2.
[CrossRef] [PubMed]
Toxins 2017, 9, 49 17 of 18
15. Scheutz, F.; Teel, L.D.; Beutin, L.; Piérard, D.; Buvens, G.; Karch, H.; Mellmann, A.; Caprioli, A.; Tozzoli, R.;
Morabito, S.; et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and
standardizing Stx nomenclature. J. Clin. Microbiol. 2012, 50, 2951–2963. [CrossRef] [PubMed]
16. Obata, F.; Obrig, T. Role of Shiga/Vero toxins in pathogenesis. Microbiol. Spectrum 2014, 2. [CrossRef]
[PubMed]
17. Petruzziello-Pellegrini, T.N.; Marsden, P.A. Shiga toxin-associated hemolytic uremic syndrome: Advances in
pathogenesis and therapeutics. Curr. Opin. Nephrol. Hypertens. 2012, 21, 433–440. [CrossRef] [PubMed]
18. Tzipori, S.; Chow, C.W.; Powell, H.R. Cerebral infection with Escherichia coli O157:H7 in humans and
gnotobiotic piglets. J. Clin. Pathol. 1988, 41, 1099–1103. [CrossRef] [PubMed]
19. Francis, D.H.; Moxley, R.A.; Andraos, C.Y. Edema disease-like brain lesions in gnotobiotic piglets infected
with Escherichia coli serotype O157:H7. Infect. Immun. 1989, 57, 1339–1342. [PubMed]
20. Chae, C.; Moxley, R.A.; Christopher-Hennings, J.; Francis, D.H.; Wannemuehler, M.J. Shiga-like
toxin-II-producing Escherichia coli O157:H7 infection in gnotobiotic piglets: Protection against brain vascular
lesions with SLT-II antiserum. In Recent Advances in Verocytotoxin Producing Escherichia coli Infections;
Karmali, M.A., Goglio, A.G., Eds.; Excerpta Medica, International Congress Series No. 1072; Elsevier
Science B.V.: Amsterdam, The Netherlands, 1994; pp. 241–244.
21. Donohue-Rolfe, A.; Kondova, I.; Mukherjee, J.; Chios, K.; Hutto, D.; Tzipori, S. Antibody-based protection of
gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with
Shiga toxin 2. Infect. Immun. 1999, 67, 3645–3648. [PubMed]
22. Matise, I.; Cornick, N.A.; Booher, S.L.; Samuel, J.E.; Bosworth, B.T.; Moon, H.W. Intervention with Shiga toxin
(Stx) antibody after infection by Stx-producing Escherichia coli. J. Infect. Dis. 2001, 183, 347–350. [CrossRef]
[PubMed]
23. Melton-Celsa, A.R.; O’Brien, A.D. New therapeutic developments against Shiga toxin-producing
Escherichia coli. Microbiol. Spectrum 2014, 2. [CrossRef] [PubMed]
24. Nakao, H.; Kiyokawa, N.; Fujimoto, J.; Yamasaki, S.; Takeda, T. Monoclonal antibody to Shiga toxin 2
which blocks receptor binding and neutralizes cytotoxicity. Infect. Immun. 1999, 67, 5717–5722. [CrossRef]
[PubMed]
25. Kimura, T.; Co, M.S.; Vasquez, M.; Wei, S.; Xu, H.; Tani, S.; Sakai, Y.; Kawamura, T.; Matsumoto, Y.;
Nakao, H.; et al. Development of humanized monoclonal antibody TMA-15 which neutralizes Shiga toxin 2.
Hybrid. Hybrid. 2002, 21, 161–168. [CrossRef] [PubMed]
26. Yamagami, S.; Motoki, M.; Kimura, T.; Izumi, H.; Takeda, T.; Katsuura, Y.; Matsumoto, Y. Efficacy of post
infection treatment with anti–Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally
challenged with Stx-producing Escherichia coli. J. Infect. Dis. 2001, 184, 738–742. [CrossRef] [PubMed]
27. Erume, J.; Berberov, E.M.; Kachman, S.D.; Scott, M.A.; Zhou, Y.; Francis, D.H.; Moxley, R.A. Comparison of
the contributions of heat-labile enterotoxin and heat-stable enterotoxin b to the virulence of enterotoxigenic
Escherichia coli in F4ac receptor-positive young pigs. Infect. Immun. 2008, 76, 3141–3149. [CrossRef] [PubMed]
28. Baker, D.R.; Moxley, R.A.; Steele, M.B.; LeJeune, J.T.; Christopher-Hennings, J.; Chen, D.; Hardwidge, P.R.;
Francis, D.H. Differences in virulence among Escherichia coli O157:H7 strains isolated from human disease
outbreaks and healthy cattle. Appl. Environ. Microbiol. 2007, 73, 7338–7346. [CrossRef] [PubMed]
29. Björkman, S.T.; Foster, K.A.; O’Driscoll, S.M.; Healy, G.N.; Lingwood, B.E.; Burke, C.; Colditz, P.B.
Hypoxic/Ischemic models in newborn piglet: comparison of constant FiO2 versus variable FiO2 delivery.
Brain Res. 2006, 1100, 110–117. [CrossRef] [PubMed]
30. Gunzer, F.; Hennig-Pauka, I.; Waldmann, K.H.; Sandhoff, R.; Gröne, H.J.; Kreipe, H.H.; Matussek, A.;
Mengel, M. Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with
enterohemorrhagic Escherichia coli. Am. J. Clin. Pathol. 2002, 118, 364–375. [CrossRef] [PubMed]
31. Pohlenz, J.F.; Winter, K.R.; Dean-Nystrom, E.A. Shiga-toxigenic Escherichia coli-inoculated neonatal piglets
develop kidney lesions that are comparable to those in humans with hemolytic-uremic syndrome.
Infect. Immun. 2005, 73, 612–616. [CrossRef] [PubMed]
32. Mukherjee, J.; Chios, K.; Fishwild, D.; Hudson, D.; O’Donnell, S.; Rich, S.M.; Donohue-Rolfe, A.; Tzipori, S.
Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7
infection. Infect. Immun. 2002, 70, 612–619. [CrossRef] [PubMed]
33. Sheoran, A.S.; Chapman-Bonofiglio, S.; Harvey, B.R.; Mukherjee, J.; Georgiou, G.; Donohue-Rolfe, A.;
Tzipori, S. Human antibody against Shiga toxin 2 administered to piglets after the onset of diarrhea due to
Toxins 2017, 9, 49 18 of 18
Escherichia coli O157:H7 prevents fatal systemic complications. Infect. Immun. 2005, 73, 4607–4613. [CrossRef]
[PubMed]
34. Chae, C. Shiga-Like Toxin-II-Producing Escherichia coli O157:H7 Infection in Gnotobiotic Pigs. Ph.D. Thesis,
University of Nebraska Medical Center, Omaha, Nebraska, 1992.
35. Schmidt, V. Comparative Anatomy of the Pig Brain—An Integrative Magnetic Resonance Imaging (MRI)
Study of the Porcine Brain with Special Emphasis on the External Morphology of the Cerebral Cortex.
Ph.D. Thesis, University of Giessen, Giessen, Germany, 2015.
36. Moxley, R.A.; Francis, D.H. Overview of animal models. In Escherichia coli O157:H7 and Other Shiga
Toxin-Producing E. coli Strains; Kaper, J.B., O’Brien, A.D., Eds.; American Society for Microbiology Press:
Washington, DC, USA, 1998; pp. 249–260.
37. Tzipori, S.; Sheoran, A.; Akiyoshi, D.; Donohue-Rolfe, A.; Trachtman, H. Antibody therapy in the
management of Shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 2004, 17, 926–941.
[CrossRef] [PubMed]
38. Ritchie, J.M. Animal models of enterohemorrhagic Escherichia coli infection. Microbiol. Spectr. 2014, 2.
[CrossRef] [PubMed]
39. Hahn, J.S.; Havens, P.L.; Higgins, J.J.; O’Rourke, P.P.; Estroff, J.A.; Strand, R. Neurological complications of
hemolytic-uremic syndrome. J. Child Neurol. 1989, 4, 108–113. [CrossRef] [PubMed]
40. Jeong, Y.K.; Kim, L.-O.; Kim, W.S.; Hwang, Y.S.; Choi, Y.; Yeon, K.M. Hemolytic uremic syndrome:
MR findings of CNS complications. Pediatr. Radiol. 1994, 24, 585–586. [CrossRef] [PubMed]
41. Schmidt, S.; Gudinchet, F.; Meagher-Villemure, K.; Maeder, P. Brain involvement in haemolytic-uraemic
syndrome: MRI features of coagulative necrosis. Neuroradiology 2001, 43, 581–585. [CrossRef] [PubMed]
42. Nathanson, S.; Kwon, T.; Elmaleh, M.; Charbit, M.; Launay, E.A.; Harambat, J.; Brun, M.; Ranchin, B.;
Bandin, F.; Cloarec, S.; et al. Acute neurological involvement in diarrhea-associated hemolytic uremic
syndrome. Clin. J. Am. Soc. Nephrol. 2010, 5, 1218–1228. [CrossRef] [PubMed]
43. Magnus, T.; Röther, J.; Simova, O.; Meier-Cillien, M.; Repenthin, J.; Möller, F.; Gbadamosi, J.; Panzer, U.;
Wengenroth, M.; Hagel, C.; et al. The neurological syndrome in adults during the 2011 northern German
E. coli serotype O104:H4 outbreak. Brain 2012, 135, 1850–1859. [CrossRef] [PubMed]
44. Donohue-Rolfe, A.; Kondova, I.; Oswald, S.; Hutto, D.; Tzipori, S. Escherichia coli O157:H7 strains that express
Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isolates producing only Stx1 or
both Stx1 and Stx2. J. Infect. Dis. 2000, 181, 1825–1829. [CrossRef] [PubMed]
45. Dykstra, S.A.; Moxley, R.A.; Janke, B.H.; Nelson, E.A.; Francis, D.H. Clinical signs and lesions in gnotobiotic
pigs inoculated with Shiga-like toxin I from Escherichia coli. Vet. Pathol. 1993, 30, 410–417. [CrossRef]
[PubMed]
46. Karniychuk, U.U.; Nauwynck, H.J. Pathogenesis and prevention of placental and transplacental porcine
reproductive and respiratory syndrome virus infection. Vir. Res. 2013, 44. [CrossRef] [PubMed]
47. Paul, P.S.; Halbur, P.; Janke, B.; Joo, H.; Nawaqitqul, P.; Singh, J.; Sorden, S. Exogenous porcine viruses.
Curr. Top. Microbiol. Immunol. 2003, 278, 125–183. [PubMed]
48. Miniats, O.P.; Jol, D. Gnotobiotic pigs-derivation and rearing. Can. J. Comp. Med. 1978, 42, 428–437. [PubMed]
49. Lee, J.Y.; Kim, M.C. Anesthesia of growing pigs with tiletamine-zolazepam and reversal with flumazenil.
J. Vet. Med. Sci. 2012, 74, 335–339. [CrossRef] [PubMed]
50. AVMA Guidelines on Euthanasia. Available online: http://grants.nih.gov/grants/olaw/Euthanasia2007.pdf
(accessed on 6 October 2016).
© 2017 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
